Association Between Classes of Antidiabetic Medications and Their Potential Risk or Protective Effects on Cancer: A Systematic Review and Network Meta-Analysis
Speaker(s)
Kenawy A1, Liu YS1, Aiyeolemi A1, Okoye G1, Park C2
1The University of Texas at Austin, Austin, TX, USA, 2The University of Texas at Austin, Austin, Texas, TX, USA
Presentation Documents
OBJECTIVES: Current literature lacks conclusive evidence regarding the potential risk or protective effects on cancer associated with novel antidiabetic medications. Based on real-world evidence, this systematic review and network meta-analysis aims to compare the potential cancer risks or protective effects associated with these novel antidiabetic medications.
METHODS: We systematically searched PubMed, CINAHL, and Web of Science until November 2023. For the systematic review, we included observational studies that involved at least one class of novel antidiabetic medications (sodium-glucose cotransporter-2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, and glucagon-like peptide-1 (GLP-1) agonists) in the intervention arm. For the network meta-analysis (NMA), we limited our selection to cohort studies that reported cancer incidence and sample size. A random-effects model with informative priors was used in the NMA to estimate the pooled odds ratio (OR) with 95% credible intervals (CI) based on the Bayesian framework using NetMetaXL®.
RESULTS: Out of the 62 studies (53 cohorts and 9 case-control) in our systematic review, 22 studies were included in the NMA. SGLT-2 inhibitors were likely to reduce the overall cancer risk compared to sulfonylureas (OR:0.54; 95%CI: 0.40 – 0.74), GLP-1 agonists (OR:0.70; 95%CI: 0.53 – 0.92), and DPP-4 inhibitors (OR:0.72; 95%CI: 0.57 – 0.92). DPP-4 inhibitors were also associated with a lower risk of cancer compared to sulfonylureas (OR:0.76; 95%CI: 0.60 – 0.96). No statistically significant odds ratios were observed in other head-to-head comparisons in our NMA.
CONCLUSIONS: SGLT-2 inhibitors are associated with protective effects against developing cancer compared to sulfonylureas, GLP-1 agonists, and DPP-4 inhibitors. These results may influence clinical practice by guiding medication choices with a focus on patient safety. Further studies are needed to explore the mechanisms behind this observed association.
Code
CO2
Topic
Clinical Outcomes, Epidemiology & Public Health, Study Approaches
Topic Subcategory
Comparative Effectiveness or Efficacy, Literature Review & Synthesis, Meta-Analysis & Indirect Comparisons
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), Oncology